Evidence map›Paper›PMID 30160789›Full record

Trial reportAmerican journal of hematology2018

Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study.

Ming-Hua Yang, Wu-Qing Wan, Jie-Si Luo, Min-Cui Zheng, Ke Huang, Li-Hua Yang, Hui-Rong Mai, Jian Li, Hui-Qin Chen, Xiao-Fei Sun and 8 more

Open access · bronzeAbstract readMulticenter StudyRandomized Controlled TrialEquivalence Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Arsenic trioxideHaematologica · 2025
    Trial
  4. Trial
  5. Trial
  6. Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
    Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 1 country.

Ming-Hua YangDepartment of Pediatrics, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Wu-Qing WanDepartment of Pediatrics, Second Xiangya Hospital, Central South University, Hunan, China.
Jie-Si LuoDepartment of Pediatrics, First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Min-Cui ZhengDepartment of Hematology, Hunan Childdren's Hospital, Changsha, Hunan, China.
Ke HuangDepartment of Pediatrics, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Li-Hua YangDepartment of Pediatrics, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Hui-Rong MaiDepartment of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen, China.
Jian LiDepartment of Pediatric Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
Hui-Qin ChenDepartment of Pediatrics, Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Xiao-Fei SunDepartment of Pediatrics, Sun Yat-Sen University Cancer Center, Guanzhou, China.
Ri-Yang LiuDepartment of Pediatrics, Huizhou Municipal Central Hospital, Huizhou, Guangdong, China.
Guo-Hua ChenDepartment of Pediatrics, First People's Hospital of Huizhou, Huizhou, Guangdong, China.
Xiaoqin FengDepartment of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Zhi-Yong KeDepartment of Pediatrics, First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Bin LiClinical Trials Unit, First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Yan-Lai TangDepartment of Pediatrics, First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Li-Bin HuangDepartment of Pediatrics, First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Xue-Qun LuoDepartment of Pediatrics, First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.ORCID 0000-0001-8473-5343
Sun Yat-sen University · CNCentral South University · CNHuizhou Central People's Hospital · CNFujian Medical University · CNHunan Children's Hospital · CNNanfang Hospital · CNShenzhen Children's Hospital · CNZhujiang Hospital · CN

Funding

Sun Yat-Sen University Clinical Research 5010 Program 2010001The Science and Technology Planning Project of Guangdong Province, China 2014A020221008The Science and Technology Planning Project of Guangzhou, China 201604020128
6 · The paper itself

Abstract

Intravenous arsenic trioxide (ATO) has been adopted as the first-line treatment for acute promyelocytic leukemia (APL). Another arsenic compound named the Realgar-Indigo naturalis formula (RIF), an oral traditional Chinese medicine containing As

Indexed as

AdolescentArsenic TrioxideChildChild, PreschoolDisease-Free SurvivalDrugs, Chinese HerbalHumansInfantLength of StayLeukemia, Promyelocytic, AcuteMaleTreatment OutcomeTretinoinArsenic TrioxideDrugs, Chinese Herbalrealgar-indigo naturalisTretinoin

Identifiers

PMID30160789
PMCPMC6282847
OpenAlexW2889022305

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.